Loading...
Loading...
AVTE| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 15.9M |
| Operating I/L | -15.9M |
| Other Income/Expense | 0.9M |
| Interest Income | 0.9M |
| Pretax | -15.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -15.0M |
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of drugs for rare cardiopulmonary diseases. Their primary focus is on advancing AV-101, a dry powder inhaled formulation of imatinib, for the treatment of pulmonary arterial hypertension. The company generates revenue through the development and potential commercialization of innovative drug therapies aimed at enhancing the lives of patients with these conditions.
